The findings, published in the March issue of Gastroenterology, revealed no significant difference in positive predictive value between average risk patients who received a guaiac fecal occult blood test in the first round and those who received a fecal immunochemical test in the first round.
Researchers said, however, that “no large difficulties are to be expected should a switch from a guaiac-based program to a FIT-based program be desired in screening programs currently using guaiac tests.”
Related Articles on GI and Endoscopy:
Kentucky Public-Private Partnership to Fund Colon Cancer Screenings for the Uninsured
Regulators Work to Limit Weight Loss Pill Qnexa, Citing Safety Concerns
Dr. Joseph Brasco: 5 Points on Fecal Microbiota Transplant in an ASC
